Key statistics
On Friday, Harrow Inc (HROWL:NMQ) closed at 25.36, -1.42% below its 52-week high of 25.73, set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.39 |
---|---|
High | 25.40 |
Low | 25.32 |
Bid | 25.32 |
Offer | 25.44 |
Previous close | 25.43 |
Average volume | 3.95k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 2.16 USD |
---|---|
Annual div yield (ADY) | 8.50% |
Div ex-date | Oct 15 2024 |
Div pay-date | Oct 31 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 20:49 GMT.
More ▼
Press releases
- OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
- Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
- Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
- Harrow Announces Participation in Upcoming Investor Conferences
- Harrow Announces Third Quarter 2024 Financial Results
- Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
- Harrow Announces Market Access Wins for VEVYE®
- Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
- Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
- Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
More ▼